scholarly journals Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature

2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Pongprueth Rujirachun ◽  
Apichaya Junyavoraluk ◽  
Weerapat Owattanapanich ◽  
Voraparee Suvannarerg ◽  
Sirinart Sirinvaravong
Onkologie ◽  
2012 ◽  
Vol 35 (11) ◽  
pp. 690-693 ◽  
Author(s):  
Kmira Zahra ◽  
Wafa Ben Fredj ◽  
Yosra Ben Youssef ◽  
Houneida Zaghouani ◽  
Imène Chebchoub ◽  
...  

1999 ◽  
Vol 23 (9) ◽  
pp. 851-854 ◽  
Author(s):  
P Solves ◽  
P Bolufer ◽  
J.A López ◽  
E Barragán ◽  
L Bellod ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Bader Alharbi ◽  
Samer Alamri ◽  
Ahmed Mahdi ◽  
Siham Marghalani

Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacious in treating imatinib-resistant chronic myeloid leukemia (CML) or intolerant cases. Noncutaneous adverse effects with dasatinib are well known in the literature, most commonly cytopenias and fluid retention, while pigmentary abnormalities have rarely been reported. We report the case of a 12-year-old male known case of CML, who presented to dermatology clinic approximately 2 years after initiating dasatinib treatment, with new-onset hypopigmentation of his upper limb, upper chest, and both knees of six months’ duration.


2009 ◽  
Vol 33 (8) ◽  
pp. 1079-1081 ◽  
Author(s):  
Salvatore Guastafierro ◽  
Umberto Falcone ◽  
Maria Celentano ◽  
Milena Coppola ◽  
Maria Giovanna Ferrara ◽  
...  

Transfusion ◽  
2017 ◽  
Vol 58 (2) ◽  
pp. 456-460 ◽  
Author(s):  
Elizabeth M. Staley ◽  
Sierra C. Simmons ◽  
Alexander Z. Feldman ◽  
Robin G. Lorenz ◽  
Marisa B. Marques ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document